Nitinotes’ is engaged in the fight against obesity, one of the fastest-growing illnesses in the world. According to the World Health Organization, around 650 million people around the globe are classified as obese, triple the total in 1975. Until now, treating this disease has been a demanding challenge, rarely successful for any prolonged period of time, involving three different approaches:
Nitinotes, however, has developed a fourth approach with the creation and development of EndoZipTM, a fully automated, operator-independent, minimally invasive suturing system. This solution enables durable endoluminal restrictive sutures in patients who are obese.
As a long-term investor with a track record of creating successful and sustainable businesses, our goal is to deliver attractive strategic and financial returns to our investors.